Bioprocess engineering issues that would be faced in producing a DNA vaccine at up to 100 m3 fermentation scale for an influenza pandemic

Biotechnology Progress

Volumn 21, Issue 6, 2005, Pages 1577-1592

  Hoare, Mike ^a   Levy, M Susana ^a   Bracewell, Daniel G ^a   Doig, Steven D ^a   Kong, Simyee ^a   Titchener Hooker, Nigel ^a   Ward, John M ^a   Dunnill, Peter ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTICS; BIOMEDICAL ENGINEERING; DNA; DRUG PRODUCTS PLANTS; FERMENTATION; VACCINES;

BIOPROCESS ENGINEERING; INFLUENZA PANDEMIC; PUBLIC DOMAIN INFORMATION; WORLD HEALTH ORGANIZATION (WHO);

BIOTECHNOLOGY;

DNA VACCINE; INFLUENZA VACCINE;

ADSORPTION; BIOMEDICAL ENGINEERING; BIOREACTOR; BIOTECHNOLOGY; CHEMISTRY; CHROMATOGRAPHY; EPIDEMIC; ESCHERICHIA COLI; FERMENTATION; GENETICS; HEAT; HUMAN; INFLUENZA; ISOLATION AND PURIFICATION; METHODOLOGY; PH; PLASMID; PRECIPITATION; REVIEW; ULTRAFILTRATION;

ADSORPTION; BIOMEDICAL ENGINEERING; BIOREACTORS; BIOTECHNOLOGY; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY; DISEASE OUTBREAKS; ESCHERICHIA COLI; FERMENTATION; FRACTIONAL PRECIPITATION; HEAT; HUMANS; HYDROGEN-ION CONCENTRATION; INFLUENZA VACCINES; INFLUENZA, HUMAN; PLASMIDS; ULTRAFILTRATION; VACCINES, DNA;

EID: 28844490036     PISSN: 87567938     EISSN: None     Source Type: Journal    
DOI: 10.1021/bp050190n     Document Type: Review

References (135)

1. Stohr, K.; Esveld, M. Public health. Will vaccines be available for the next influenza pandemic? Science 2004, 306, 2195-2196.
2. Aldhous, P. Avian flu supplement. Nature 2005, 435, 399-424.
3. Kaiser, J. Influenza: girding for disaster. Facing down pandemic flu, the world's defenses are weak. Science 2004, 306, 394-397.
4. Ungchusak, K.; Auewarakul, P.; Dowell, S. F.; Kitphati, R.; Auwanit, W.; Puthavathana, P.; Uiprasertkul, M.; Boonnak, K.; Pittayawonganon, C.; Cox, N. J.; Zaki, S. R.; Thawatsupha, P.; Chittaganpitch, M.; Khontong, R.; Simmerman, J. M.; Chunsutthiwat, S. Probable person-to-person transmission of avian influenza A (H5N1). N. Engl. J. Med. 2005, 352, 333-340.
5. Fedson, D. Preparing for pandemic vaccination: an international policy agenda for vaccine development. J. Public Health Policy 2005, 26, 4-29.
6. Nguyen-Van-Tam, J. S.; Hampson, A. W. The epidemiology and clinical impact of pandemic influenza. Vaccine 2003, 21, 1762-1768.
7. Gerdil, C. The annual production cycle for influenza vaccine. Vaccine 2003, 21, 1776-1779.
8. Webby, R. J.; Perez, D. R.; Coleman, J. S.; Guan, Y.; Knight, J. H.; Govorkova, E. A.; McClain-Moss, L. R.; Peiris, J. S.; Rehg, J. E.; Tuomanen, E. I.; Webster, R. G. Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines. Lancet 2004, 363, 1099-1103.
9. Murphy, M. Pandemic vaccine "a step away". Chem. Ind. 2004, Dec 6, 8.
10. Ulmer, J. B. Influenza DNA vaccines. Vaccine 2002, 20 Suppl 2, S74-S76.
11. Soboll, G.; Horohov, D. W.; Aldridge, B. M.; Olsen, C. W.; McGregor, M. W.; Drape, R. J.; Macklin, M. D.; Swain, W. F.; Lunn, D. P. Regional antibody and cellular immune responses to equine influenza virus infection, and particle mediated DNA vaccination. Vet. Immunol. Immunopathol. 2003, 94, 47-62.
12. Donnelly, J. J.; Dwarki, V. J.; Liu, M. A.; Montgomery, D. L.; Parker, S. E.; Shiver, J. W.; Ulmer, J. B. Nucleic acid pharmaceuticals-influenza matrix. U.S. Patent Application 20040087521, 2004.
13. Mwau, M.; Cebere, I.; Sutton, J.; Chikoti, P.; Winstone, N.; Wee, E. G.; Beattie, T.; Chen, Y. H.; Dorrell, L.; McShane, H.; Schmidt, C.; Brooks, M.; Patel, S.; Roberts, J.; Conlon, C.; Rowland-Jones, S. L.; Bwayo, J. J.; McMichael, A. J.; Hanke, T. A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J. Gen. Virol. 2004, 85, 911-919.
14. Perkel, J. M. Human Ebola vaccine trial begins. Scientist 2003, Nov. 24
15. Wang, R.; Doolan, D. L.; Le, T. P.; Hedstrom, R. C.; Coonan, K. M.; Charoenvit, Y.; Jones, T. R.; Hobart, P.; Margalith, M.; Ng, J.; Weiss, W. R.; Sedegah, M.; de Taisne, C.; Norman, J. A.; Hoffman, S. L. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998, 282, 476-480.
16. Kodihalli, S.; Goto, H.; Kobasa, D. L.; Krauss, S.; Kawaoka, Y.; Webster, R. G. DNA vaccine encoding hemagglutinin provides protective immunity against H5N1 influenza virus infection in mice. J. Virol. 1999, 73, 2094-2098.
17. Silverstein, A. M. Pure Politics and Impure Science: The Swine Flu Affair; Johns Hopkins University Press: Baltimore and London, 1981.
18. Solensky, R., Hypersensitivity reactions to beta-lactam antibiotics. Clin. Rev. Allergy Immunol. 2003, 24, 201-220.
19. Tilles, S. A.; Slatore, C. G. Hypersensitivity reactions to non-beta-lactam antibiotics. Clin. Rev. Allergy Immunol. 2003, 24, 221-228.
20. Durland, R. H.; Eastman, E. M. Manufacturing and quality control of plasmid-based gene expression systems. Adv. Drug Delivery Rev. 1998, 30, 33-48.
21. Levy, M. S.; O'Kennedy, R. D.; Ayazi-Shamlou, P.; Dunnill, P., Biochemical engineering approaches to the challenges of producing pure plasmid DNA. Trends Biotechnol. 2000, 18, 296-305.
22. Ferreira, G. N.; Monteiro, G. A.; Prazeres, D. M.; Cabral, J. M. Downstream processing of plasmid DNA for gene therapy and DNA vaccine applications. Trends Biotechnol. 2000, 18, 380-388.
23. Ayazi-Shamlou, P. Scaleable processes for the manufacture of therapeutic quantities of plasmid DNA. Biotechnol. Appl. Biochem. 2003, 37, 207-218.
24. Prazeres, D. M. F.; Ferreira, G. N. M. Design of flowsheets for the recovery and purification of plasmids for gene therapy and DNA vaccination. Chem. Eng. Process. 2004, 43, 615-630.
25. Prather, K. J.; Sagar, S.; Murphy, J.; Chartrain, M. Industrial scale production of plasmid DNA for vaccine and gene therapy: plasmid design, production and purification. Enzyme Microb. Technol. 2003, 33, 865-883.
26. Marquet, M.; Horn, N. A.; Meek, J. A.; Little, L. E. Characterization of plasmid DNA vectors for use in human gene therapy, part 2. BioPharm 1997, 40-50.
27. Schleef, M. Issues for large-scale plasmid DNA maufacturing in biotechnology: a multi-volume comprehensive treatise. In Recombinant Proteins, Monoclonal Antibodies, and Therapeutic Genes; Rehm, H. J., Reed, G., Eds.; Wiley-VCH: New York, 1999; Vol. 5a, pp 443-470.
28. Zhao, Y.; Thorpe, R. Standardisation of gene therapy products: Practical consideration and perspectives. Bioproc. J. 2004, 21-25. (www. bioprocessingjournal.com)
29. Holmes, D. S.; Quigley, M. A rapid boiling method for the preparation of bacterial plasmids. Anal. Biochem. 1981, 114, 193-197.
30. Birnboim, H. C.; Doly, J. A rapid alkaline extraction procedure for screening recombinant plasmid DNA. Nucleic Acids Res. 1979, 7, 1513-1523.
31. Middaugh, C. R.; Evans, R. K.; Montgomery, D. L.; Casimiro, D. R. Analysis of plasmid DNA from a pharmaceutical perspective. J. Pharm Sci. 1998, 87, 130-146.
32. Levy, M. S.; Lotfian, P.; O'Kennedy, R.; Lo-Yim, M. Y.; Shamlou, P. A. Quantitation of supercoiled circular content in plasmid DNA solutions using a fluorescence-based method. Nucleic Acids Res. 2000, 28, E57.
33. Rock, C.; Shamlou, P. A.; Levy, M. S. An automated microplate-based method for monitoring DNA strand breaks in plasmids and bacterial artificial chromosomes. Nucleic Acids Res. 2003, 31, e65.
34. Molloy, M. J.; Hall, V. S.; Bailey, S. I.; Griffin, K. J.; Faulkner, J.; Uden, M. Effective and robust plasmid topology analysis and the subsequent characterization of the plasmid isoforms thereby observed. Nucleic Acids Res. 2004, 32, e129.
35. Schleef, M.; Schmidt, T. Animal-free production of ccc-supercoiled plasmids for research and clinical applications. J. Gene Med. 2004, 6 Suppl 1, S45-S53.
36. Levy, M. S.; Collins, I. J.; Yim, S. S. S.; Ward, J. M.; Titchener-Hooker, N. J.; Shamlou, P. A.; Dunnill, P. Effect of shear on plasmid DNA solution. Bioprocess Eng. 1999, 20, 7-13.
37. Onyeaka, H.; Nienow, A. W.; Hewitt, C. J. Further studies related to the scale-up of high cell density Escherichia coli fed-batch fermentations: the additional effect of a changing microenvironment when using aqueous ammonia to control pH. Biotechnol. Bioeng. 2003, 84, 474-484.
38. Bylund, F.; Guillard, F.; Enfors, S. O.; Larsson, G. Substrate gradient formatioin in the large-scale bioreactor lowers cell yield and increases byproduct formation. Bioprocess Eng. 1998, 18, 171-180.
39. Bylund, F.; Guillard, F.; Enfors, S. O.; Tragardh, C.; Larsson, G. Scale down of recombinant protein production: a comparative study of scaling performance. Bioprocess Eng. 1999, 20, 377-389.
40. Bylund, F.; Castan, A.; Mikkola, R.; Veide, A.; Larsson, G. Influence of scale-up on the quality of recombinant human growth hormone. Biotechnol. Bioeng. 2000, 69, 119-128.
41. Junker, B. H. Scale-up methodologies for Escherichia coli and yeast germentation processes. J. Biosci. Bioeng. 2004, 97, 347-364.
42. Zhang, J.; Greasham, R. Chemically defined media for commercial fermentations. Appl. Microbiol. Biotechnol. 1999, 51, 407-421.
43. Chen, W.; Graham, C.; Ciccarelli, R. B. Automated fed-batch fermentation with feed-back controls based on dissolved oxygen (DO) and pH for production of DNA vaccines. J. Ind. Microbiol. Biotechnol. 1997, 18, 43-48.
44. Chen, W. Automated high-yield fermentation of plasmid DNA in Escherichia coli. U.S. Patent 5,955,323, 1999.
45. O'Kennedy, R. D.; Ward, J. M.; Keshavarz-Moore, E. Effects of fermentation strategy on the characteristics of plasmid DNA production. Biotechnol. Appl. Biochem. 2003, 37, 83-90.
46. Schmidt, T.; Friehs, K.; Schleef, M.; Voss, C.; Flaschel, E. In-process analysis of plasmid copy number for fermentation control. Pacesetter 2001, 5, 4-6.
47. Schmidt, T.; Friehs, K; Flaschel, E.; Schleef, M. Method for the isolation of ccc-plasmid DNA. U.S. Patent 6,664,078, 2003.
48. Voss, C.; Schmidt, T.; Schleef, M.; Friehs, K.; Flaschel, E. Effect of ammonium chloride on plasmid DNA prodction in high cell density batch culture for biopharmaceutical use. J. Chem. Technol. Biotechnol. 2004, 79, 57-62.
49. Chartrain, M. Process development for the production of plasmid DNA by cultivation of E. coli in bioreactors (Merck). In DNA Vaccines Forum; Marcus Evans Conferences: London, 2005.
50. O'Kennedy, R. D.; Baldwin, C.; Keshavarz-Moore, E. Effects of growth medium selection on plasmid DNA production and initial processing steps. J. Biotechnol. 2000, 76, 175-183.
51. Rozkov, A.; Avignone-Rossa, C. A.; Ertl, P. F.; Jones, P.; O'Kennedy, R. D.; Smith, J. J.; Dale, J. W.; Bushell, M. E. Characterization of the metabolic burden on Escherichia coli DH1 cells imposed by the presence of a plasmid containing a gene therapy sequence. Biotechnol. Bioeng. 2004, 88, 909-915.
52. Pearson, C. R.; Heng, M.; Gebert, M.; Glatz, C. E. Extracellular enzyme loss during polyelectrolyte flocculation of cells from fermentation broth. Biotechnol. Bioeng. 2004, 87, 61-68.
53. Gray, P. P.; Dunnill, P.; Lilly, M. D. The continuous-flow isolation of enzymes. In Fermentation Technology Today; Terui, G., Ed.; Pub. Soc. Fermentation Technology: Japan, 1972; pp 347-351.
54. Higgins, J. J.; Lewis, D. J.; Daly, W. H.; Mosqueira, F. G.; Dunnill, P.; Lilly, M. D. Investigation of the unit operations involved in the continuous flow isolation of beta-galactosidase from E. coli. Biotechnol. Bioeng. 1978, 20, 159-182.
55. Nagata, N.; Herouvis, K. J.; Dziewulski, D. M.; Belfort, G. Cross-flow membrane microfiltration of a bacterial fermentaion broth. Biotechnol. Bioeng. 1989, 34, 447-466.
56. Riesmeier, B.; Kroner, K. H.; Kula, M.-R. Tangential filtration of microbial suspensions: filtration resistance and model development. J. Biotechnol. 1989, 12, 153-172.
57. Bailey, F. J.; Warf, R. T.; Maigetter, R. Z. Harvesting recombinant microbial cells using cross-flow filtration. Enzyme Microb. Technol. 1990, 12, 647-652.
58. Lander, R.; Winters, M.; Meacle, F. Process for the scaleable purification of plasmid DNA. U.S. Patent application 20050019896, 2005.
59. Stratton, J.; Meagher, M. M. Effect of membrane pore size and chemistry on the cross-flow filtration of Escherichia coli and Saccharomyces cerevisiae: Simultaneous evaluation of different membranes using a versitle flat-sheet membrane module. Bioseparation 1994, 4, 255-262.
60. Meyer, F.; Gehmlich, I.; Guthke, R.; Gorak, A.; Knorre, W. A. Analysis and simulation of complex interactions during dynamic microfiltration of Escherichia coli suspensions. Biotechnol. Bioeng. 1998, 59, 189-202.
61. Ciccolini, L. A.; Shamlou, P. A.; Titchener-Hooker, N. J.; Ward, J. M.; Dunnill, P. Time course of SDS-alkaline lysis of recombinant bacterial cells for plasmid release. Biotechnol. Bioeng. 1998, 60, 768-770.
62. Ciccolini, L. A.; Shamlou, P. A.; Titchener-Hooker, N.; Ward, J.; Dunnill, P. Rheological properties of chromosomal and plasmid DNA during alkaline lysis reaction. Bioprocess Eng. 1999, 21, 231-237.
63. Ciccolini, L. A.; Shamlou, P. A.; Titchener-Hooker, N. A mass balance study to assess the extent of contaminant removal achieved in the operations for the primary recovery of plasmid DNA from Escherichia coli cells. Biotechnol. Bioeng. 2002, 77, 796-805.
64. Meacle, F. J.; Lander, R.; Ayazi Shamlou, P.; Titchener-Hooker, N. J. Impact of engineering flow conditions on plasmid DNA yield and purity in chemical cell lysis operations. Biotechnol. Bioeng. 2004, 87, 293-302.
65. Chamsart, S.; Patel, H.; Hanak, J. A.; Hitchcock, A. G.; Nienow, A. W. The impact of fluid-dynamic-generated stresses on chDNA and pDNA stability during alkaline cell lysis for gene therapy products. Biotechnol. Bioeng. 2001, 75, 387-392.
66. Nienow, A. W.; Hitchcock, A. G.; Riley, G. L. Vessel for mixing a cell lysate. U.S. Patent 6,395,516, 2002.
67. Adam, R. E.; Zimm, B. H. Shear degradation of DNA. Nucleic Acids Res. 1977, 4, 1513-1537.
68. Wan, N. C.; McNeilly, D. S.; Christopher, C. W. Method for lysing cells. U.S. Patent 5,837,529, 1998.
69. McNeilly, D. Method for purifying plasmid DNA and plasmid DNA substantially free of genomic DNA. WO Patent 99/29832, 1999.
70. Lee, A.; Sagar, S. A method for large scale plasmid purification. WO Patent 96/36706, 1996.
71. Watson, N. Non-chromatographic plasmid purification: optimisation and large scale process challenges (Merck). In DNA Vaccines Forum; Marcus Evans Conferences: London, 2005.
72. Kresheck, G. C.; Altschuler, M. Method of isolating purified plasmid DNA using a nonionic detergent solution. U.S. Patent 5,625,053, 1997.
73. Wang, Z.; Le, G.; Shi, Y.; Wegrzyn, G. Studies on recovered plasmid DNA from Escherichia coli by heat treatment. Process Biochem. 2002, 38, 199-206.
74. Thatcher, D.; Hitchcock, A.; Hanak, J.; Varley, D. Method of plasmid DNA production and purification. WO Patent 97/29190, 1997.
75. Horn, N.; Marquet, M.; Meek, J.; Budahazi, G. Process for reducing RNA concentration in a mixture of biological material using diatomaceous earth. WO Patent 96/21729, 1996.
76. Theodossiou, I.; Thomas, O. R. T.; Dunnill, P. Methods of enhancing the recovery of plasmid genes from neutralized cell lysate using filtration and/or flotation. Bioprocess Eng. 1999, 20, 147-156.
77. Reynolds, T.; Boychyn, M.; Sanderson, T.; Bulmer, M.; More, J.; Hoare, M. Scale-down of continuous filtration for rapid bioprocess design: Recovery and dewatering of protein precipitate suspensions. Biotechnol. Bioeng. 2003, 83, 454-464.
78. Theodossiou, I.; Collins, I. J.; Ward, J. M.; Thomas, O. R. T.; Dunnill, P. The processing of a plasmid-based gene from E. coli. Primary recovery by filtration. Bioprocess Eng. 1997, 16, 175-183.
79. Gray, P. P.; Dunnill, P.; Lilly, M. D. The clarification of mechanically disrupted yeast suspensions by rotary vaccum precoat filtration. Biotechnol. Bioeng. 1973, 15, 309-320.
80. Hilbrig, F.; Freitag, R.; Schumacher, I. Method for treating biomass for producing cell lysate containing plasmid DNA. U.S. Patent application 20040014098, 2004.
81. De Jonge, E.; van Leeuwen, M. A. W.; Radema, H.; Lissen, P. H. J. M.; Over, J. Filtration process in the Cohn fractionation. Colloque INSERM/John Libbey Eurotext Ltd: France, 1993; Vol. 227, p 49-54.
82. Wolter, D. The use of coarse filtration for separation of plasma fractions. Proceedings of the international workshop on technology for protein separation and improvement of blood plasma fractionation. In DHEW Pub. No. (NH) 78-1422: Washington, DC, 1977; pp 129-132.
83. Johnston, A.; Davies, J. R.; Turner, P.; Wilkie, B. J. Filtration of plasma mixtures using cellulose-based filter aids. WO Patent 97/32654, 1997.
84. Zhang, S.; Krivosheyeva, A.; Nochumson, S. Large-scale capture and partial purification of plasmid DNA using anion-exchange membrane capsules. Biotechnol. Appl. Biochem. 2003, 37, 245-249.
85. Wright, J. L.; Jordan, M.; Wurm, M. Extraction of plasmid DNA using reactor scale alkaline lysis and selective precipitation for scalable transient transfection. Cytotechnology 2001, 35, 165-173.
86. Breul, A. Innovation in process technology for plasmid DNA manufacturing (Qiagen). In DNA Vaccines Forum; Marcus Evans Conferences: London, 2005.
87. Boychyn, M.; Yim, S. S. S.; Shamlou, P. A.; Bulmer, M.; More, J.; Hoare, M. Characterization of flow intensity in continuous centrifuges for the development of laboratory mimics. Chem. Eng. Sci. 2001, 56, 4659-4670.
88. Sandberg, L. M.; Nilsson, R.; Hakansson, E.; Anderson, A.; Vasi, J.; Lemmens, R. Scale-up of a cost-effective and generic purification process for plasmid DNA. Life Science News, Amersham Bioscience, 2004, 16.
89. Kendall, D.; Lye, G. J.; Levy, M. S. Purification of plasmid DNA by an integrated operation comprising tangential flow filtration and nitrocellulose adsorption. Biotechnol. Bioeng. 2002, 79, 816-822.
90. Lander, R. J.; Winters, M. A.; Meacle, F. J.; Buckland, B. C.; Lee, A. L. Fractional precipitation of plasmid DNA from lysate by CTAB. Biotechnol. Bioeng. 2002, 79, 776-784.
91. Lander, R.; Winters, M.; Meacle, F. Process for the scaleable purification of plasmid DNA. WO Patent 01/46215 A1, 2001.
92. Lis, J. T.; Schleif, R. Size fractionation of double-stranded DNA by precipitation with polyethylene glycol. Nucleic Acids Res. 1975, 02, 383-389.
93. Murphy, J. C.; Winters, M. A.; Watson, M. P.; Konz, J. O.; Sagar, S. L. Monitoring of RNA clearance in novel plasmid DNA purification process. Biotechnol. Prog. 2005, 21, 1213-1219.
94. Gani, S. A.; Chattoraj, D. K.; Mukherjee, D. C. Solubilization and binding of DNA-CTAB complex with SDS in aqueous media. Indian J. Biochem. Biophys. 1999, 36, 233-239.
95. Eon-Duval, A.; Gumbs, K.; Ellett, C. Precipitation of RNA impurities with high salt in a plasmid DNA purification process: use of experimental design to determine reaction conditions. Biotechnol. Bioeng. 2003, 83, 544-553.
96. Eon-Duval, A.; MacDuff, R. H.; Fisher, C. A.; Harris, M. J.; Brook, C. Removal of RNA impurities by tangential flow filtration in an RNase-free plasmid DNA purification process. Anal. Biochem 2003, 316, 66-73.
97. Marquet, M.; Horn, N.; Meek, J.; Budahazi, G. Production of pharmaceutical-grade plasmid DNA. WO Patent 95/29832, 1995.
98. Bussey, L. B.; Adamson, R.; Atchley, A. Methods for purifying nucleic acids. WO Patent 98/05673, 1998.
99. Kahn, D. W.; Butler, M. D.; Cohen, D. L.; Gordon, M.; Kahn, J. W.; Winkler, M. E. Purification of plasmid DNA by tangential flow filtration. Biotechnol. Bioeng. 2000, 69, 101-106.
100. Varley, D. L.; Hitchcock, A. G.; Weiss, A. M.; Horler, W. A.; Cowell, R.; Peddie, L.; Sharpe, G. S.; Thatcher, D. R.; Hanak, J. A. Production of plasmid DNA for human gene therapy using modified alkaline cell lysis and expanded bed anion exchange chromatography. Bioseparation 1999, 8, 209-217.
101. Winters, M. A.; Richter, J. D.; Sagar, S. L.; Lee, A. L.; Lander, R. J. Plasmid DNA purification by selective calcium silicate adsorption of closely related impurities. Biotechnol. Prog. 2003, 19, 440-447.
102. Ferreira, G. N.; Cabral, J. M.; Prazeres, D. M. Anion exchange purification of plasmid DNA using expanded bed adsorption. Bioseparation 2000, 9, 1-6.
103. Shepard, S. R.; Boucher, R.; Johnston, J.; Boerner, R.; Koch, G.; Madsen, J. W.; Grella, D.; Sim, B. K.; Schrimsher, J. L. Large-scale purification of recombinant human angiostatin. Protein Expression Purif. 2000, 20, 216-27.
104. Eon-Duval, A.; Burke, G. Purification of pharmaceutical-grade plasmid DNA by anion-exchange chromatography in an RNase-free process. J. Chromatogr. B 2004, 804, 327-335.
105. Theodossiou, I.; Sondergaard, M.; Thomas, O. R. Design of expanded bed supports for the recovery of plasmid DNA by anion exchange adsorption. Bioseparation 2001, 10, 31-44.
106. Bhikhabhai, R. Plasmid DNA purification using divalent alkaline earth metal ions and two anion exchangers. U.S. Patent 6,410,274, 2002.
107. Budahazi, G.; Goff, B. Process for purification of plasmid DNA. U.S. Patent application 20040157244, 2004.
108. Horn, N.; Budahazi, G.; Marquet, M. Purification of plasmid DNA during column chromatography. U.S. Patent 5,707,812, 1998.
109. Endres, H. N.; Johnson, J. A.; Ross, C. A.; Welp, J. K.; Etzel, M. R. Evaluation of an ion-exchange membrane for the purification of plasmid DNA. Biotechnol. Appl. Biochem. 2003, 37, 259-266.
110. Haber, C.; Skupsky, J.; Lee, A.; Lander, R., Membrane chromatography of DNA: conformation-induced capacity and selectivity. Biotechnol. Bioeng. 2004, 88, 26-34.
111. Ferreira, G. N.; Cabral, J. M.; Prazeres, D. M. Studies on the batch adsorption of plasmid DNA onto anion-exchange chromatographic supports. Biotechnol. Prog. 2000, 16, 416-424.
112. Ferreira, G. N.; Cabral, J. M.; Prazeres, D. M. A comparison of gel filtration chromatographic supports for plasmid purification. Biotechnol. Tech. 1997, 11, 417-420.
113. Murphy, J. C.; Jewell, D. L.; White, K. I.; Fox, G. E.; Willson, R. C. Nucleic acid separations utilizing immobilized metal affinity chromatography. Biotechnol. Prog. 2003, 19, 982-986.
114. Duarte, M.; Maria, M.; Joao, A. Purification of plasmid DNA by hydrophobic interaction chromatography. U.S. Patent application 20040038393, 2004.
115. Diogo, M. M.; Queiroz, J. A.; Prazeres, D. M. F. Chromatography of plasmid DNA. J. Chromatogr. A 2005, 1069, 3-22.
116. Gustavsson, P. E.; Lemmens, R.; Nyhammar, T.; Busson, P.; Larsson, P. O. Purification of plasmid DNA with a new type of anion-exchange beads having a noncharged surface. J. Chromatogr. A 2004, 1038, 131-140.
117. Hoare, M.; Narendranathan, T.; Flint, J. R.; Heywood-Waddington, D.; Bell, D. J.; Dunnill, P. Disruption of protein precipitates during shear in couette flow and in pumps. Ind. Eng. Chem. Fundam. 1982, 21, 402-406.
118. Anchordoquy, T. J.; Koe, G. S. Physical stability of nonviral plasmid-based therapeutics. J. Pharm. Sci. 2000, 89, 289-296.
119. Volkin, D. B.; Evans, R. K.; Bruner, M. DNA vaccine formulation. U.S. Patent application 20040138165, 2004.
120. Cooke, G. D.; Cranenburgh, R. M.; Hanak, J. A.; Dunnill, P.; Thatcher, D. R.; Ward, J. M. Purification of essentially RNA free plasmid DNA using a modified Escherichia coli host strain expressing ribonuclease A. J. Biotechnol. 2001, 85, 297-304.
121. Postlethwaite, J.; Lamping, S. R.; Leach, G. C.; Hurwitz, M. F.; Lye, G. J. Flux and transmission characteristics of a vibrating microfiltration system operated at high biomass loading. J. Membr. Sci. 2004, 228, 89-101.
122. Adikane, H. V.; Singh, R. K.; Nene, S. N. Recovery of penicillin G from fermentation broth by microfiltration. J. Membr. Sci. 1999, 162, 119-123.
123. Capuder, E. Process for the isolation of clavulanic acid and of pharmaceutically acceptable salts thereof. U.S. Patent 6,566,106, 2003.
124. Capuder, E. Isolation of clavulanic acid from fermentation broth by ultrafiltration. U.S. Patent 6,127,358, 2000.
125. Yavorsky, D.; Blanck, R.; Lambalot, C.; Brunkow, R. The clarification of bioreactor cell cultures for biopharmaceuticals. Pharm. Technol. 2003, 62-76.
126. Dix, C. Positive outcome of phase 1 DNA influenza study. PowerMed press release Nov, 2004.
127. Singh, M.; O'Hagan, D. Advances in vaccine adjuvants. Nat. Biotechnol. 1999, 17, 1075-1081.
128. Singh, M.; Briones, M.; Ott, G.; O'Hagan, D. Cationic microparticles: A potent delivery system for DNA vaccines. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 811-816.
129. Wong, J. P.; Zabielski, M. A.; Schmaltz, F. L.; Brownlee, G. G.; Bussey, L. A.; Marshall, K.; Borralho, T.; Nagata, L. P. DNA vaccination against respiratory influenza virus infection. Vaccine 2001, 19, 2461-2467.
130. Wong, J. P.; Nagata, L. P. DNA vaccine using liposome-encapsulated plasmid DNA encoding for hemagglutinin protein of influenza virus. U.S. Patent application 20030008000, 2003.
131. Liu, M. A. DNA vaccines: a review. J. Intern. Med. 2003, 253, 402-410.
132. Govorkova, E. A.; Rehg, J. E.; Krauss, S.; Yen, H. L.; Guan, Y.; Peiris, M.; Nguyen, T. D.; Hanh, T. H.; Puthavathana, P.; Long, H. T.; Buranathai, C.; Lim, W.; Webster, R. G.; Hoffmann, E. Lethality to ferrets of H5N1 influenza viruses isolated from humans and poultry in 2004. J. Virol. 2005, 79, 2191-2198.
133. Kay, A.; O'Kennedy, R.; Ward, J.; Keshavarz-Moore, E. Impact of plasmid size on cellular oxygen demand in Escherichia coli. Biotechnol. Appl. Biochem. 2003, 38, 1-7.
134. Cooke, J. R.; McKie, E. A.; Ward, J. M.; Keshavarz-Moore, E. Impact of intrinsic DNA structure on processing of plasmids for gene therapy and DNA vaccines. J. Biotechnol. 2004, 114, 239-254.
135. Shadle, P. J. The art of raw materials and supplier qualification. Bioproc. J. 2004, 3, 43-46. (www. bioprocessingjournal.com)